Lung cancer vaccines and gene therapy

Kolb, 1995, Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia, Blood, 86, 4011, 10.1182/blood.V86.5.2041.bloodjournal8652041 Albelda, 2002, Gene therapy for lung neoplasms, Lung Cancer, 23, 265 Dranoff, 1993, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity, Proc. Natl. Acad. Sci. USA, 90, 3539, 10.1073/pnas.90.8.3539 Machiels, 2001, Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice, Cancer Res., 61, 3689 Soiffer, 1998, Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma, Proc. Natl. Acad. Sci. USA, 95, 13141, 10.1073/pnas.95.22.13141 Simons, 1997, Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer, Cancer Res., 57, 1537 Jaffee, 2001, Novel allogeneic GM-CSF-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation, J. Clin. Oncol., 19, 145, 10.1200/JCO.2001.19.1.145 Salgia, 2003, Vaccination with irradiated autologous tumor cells engineered to secrete Granulocyte-Macrophage Colony Stimulating Factor augments anti-tumor immunity in patients with metastatic non-small cell lung carcinoma, J. Clin. Oncol., 21, 624, 10.1200/JCO.2003.03.091 Simons, 1999, Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer, Cancer Res., 59, 5160 Borrello, 1999, A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines, Hum. Gene Ther., 10, 1983, 10.1089/10430349950017347 Nemunaitis, 2001, A phase I/II study of autologous GM-CSF gene-modified cancer vaccines in subjects with non-small cell lung cancer (NSCLC), Proc. Am. Soc. Clin. Oncol., 20, 255a Nobel, 1978, Bronchioloalveolar cell carcinoma. Animal model: pulmonary adenomatosis of sheep, pulmonary carcinoma of sheep (jaagsiekte), Am. J. Pathol., 90, 783 Stinson, 1972, Filamentous particles in human alveolar cell carcinomas: electron microscopy studies of six cases (preliminary report), J. Natl. Cancer Inst., 49, 1483, 10.1093/jnci/49.6.1483 Jaffee, 1996, Enhanced immune priming with spatial distribution of paracrine cytokine vaccines, J. Immunother. Emphasis Tumor Immunol., 19, 176, 10.1097/00002371-199605000-00002 Ding, 1993, Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene, Cancer Immunol. Immunother., 36, 9, 10.1007/BF01789125 Palmer, 2001, Phase I study of the BLP25 (MUC1 Peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer, Clin. Lung Cancer, 3, 49, 10.3816/CLC.2001.n.018 Krug, 1999, Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination, Semin. Oncol., 26, 55 Gaugler, 1994, Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes, J. Exp. Med., 179, 921, 10.1084/jem.179.3.921 Gotoh, 1998, Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer, Lung Cancer, 20, 117, 10.1016/S0169-5002(98)00017-8 Yoshimatsu, 1998, Expression of the melanoma antigen-encoding gene in human lung cancer, J. Surg. Oncol., 67, 126, 10.1002/(SICI)1096-9098(199802)67:2<126::AID-JSO10>3.0.CO;2-1 Marchand, 1999, Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1, Int. J. Cancer, 80, 219, 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S O'Brien, 2000, A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma, Br. J. Cancer, 83, 853, 10.1054/bjoc.2000.1401 Watson, 1996, Gastrimmune raises antibodies that neutralise amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer, Cancer Res., 56, 880 Smith, 2000, Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer, Clin. Cancer Res., 6, 4719 Ishida, 1999, Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses, Clin. Exp. Immunol., 117, 244, 10.1046/j.1365-2249.1999.00913.x Nikitina, 2001, Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients, Clin. Cancer Res., 1, 2 Dickler, 1999, Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer, Clin. Cancer Res., 5, 2773 Tan, 1996, IL-2 gene therapy of advanced lung cancer patients, Anticancer Res., 16, 1993 Miller, 2000, Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication, Hum. Gene Ther., 11, 53, 10.1089/10430340050016157 Marshall, 2002, A phase I study of sequential vaccinations with fowlpox-CEA (6D)-Tricom (B7/ICAM/LFA3) alone, and in combination with vaccinia-CEA (6D)-Tricom and GM-CSF in patients with CEA expressing carcinomas, Proc. Am. Soc. Clin. Oncol., 21, 7a Robinson, 1998, Cytokine gene therapy or infusion as treatment for solid human cancer, J. Immunother., 21, 211, 10.1097/00002371-199805000-00007 Swisher, 2002, Clinical update of Ad-p53 gene therapy for lung cancer, Surg. Oncol. Clin. North Am., 11, 521, 10.1016/S1055-3207(02)00028-5 Fujiwara, 1994, Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model, J. Natl. Cancer Inst., 86, 1458, 10.1093/jnci/86.19.1458 Zhang, 1994, High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus, Cancer Gene Ther., 1, 5 Roth, 1996, Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer, Nat. Med., 2, 985, 10.1038/nm0996-985 Schuler, 1998, A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer, Hum. Gene Ther., 9, 2075, 10.1089/hum.1998.9.14-2075 Swisher, 1999, Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer, J. Natl. Cancer Inst., 91, 763, 10.1093/jnci/91.9.763 Gahery-Segard, 1997, Phase 1 trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products, J. Clin. Invest., 100, 2218, 10.1172/JCI119759 Tursz, 1996, Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients, J. Natl. Cancer Inst., 88, 1857, 10.1093/jnci/88.24.1857 Kubba, 2000, Phase I trial of adenovirus p53 in bronchioloalveolar cell lung carcinoma (BAC) administered by bronchoalveolar lavage, Proc. Am. Soc. Clin. Oncol., 19, 487a Lee, 2002, Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer, Clin. Cancer Res., 8, 2907 Gautam, 2002, Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis, Cancer Gene Ther., 9, 28, 10.1038/sj.cgt.7700405 Nemunaitis, 2000, Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer, J. Clin. Oncol., 18, 609, 10.1200/JCO.2000.18.3.609 Schuler, 2001, Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small cell lung cancer; results of a multicenter phase II study, J. Clin. Oncol., 19, 1750, 10.1200/JCO.2001.19.6.1750 Swisher, 2000, A phase II trial of adenoviral mediated p53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC), Proc. Am. Soc. Clin. Oncol., 19, 461a Swisher, 2000, Induction of pro-apoptotic mediators and tumor regression following intratumoral delivery of adenoviral p53 (RPR/INGN 201) and radiation therapy in patients with non-small cell lung cancer (NSCLC), Proc. Am. Soc. Clin. Oncol., 20, 257a Ramesh, 2001, Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppression genes using an improved liposome vector, Mol. Ther., 3, 337, 10.1006/mthe.2001.0266 Nemunaitis, 2001, Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity, Gene Ther., 8, 746, 10.1038/sj.gt.3301424 Hwang, 1995, Gene therapy using adenovirus carrying the herpes simplex thymidine kinase gene to treat in vitro models of human malignant mesothelioma and lung cancer, Am. J. Respir. Cell. Mol. Biol., 13, 7, 10.1165/ajrcmb.13.1.7598939 Pope, 1997, The role of the bystander effect in suicide gene therapy, Eur. J. Cancer, 33, 1005, 10.1016/S0959-8049(96)00483-2 Fukunaga, 2002, Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model, Ann. Thorac. Surg., 73, 1740, 10.1016/S0003-4975(02)03572-5 Sterman, 1998, Adenovirus-mediated herpes simplex virus thymidine kinase gene delivery in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma, Hum. Gene Ther., 9, 1083, 10.1089/hum.1998.9.7-1083 Sterman, 2000, A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma, Cancer Gene Ther., 7, 1511, 10.1038/sj.cgt.7700269 Rosenberg, 1987, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, New Engl. J. Med., 316, 889, 10.1056/NEJM198704093161501 Escudier, 2000, Lung Cancer, 29, 184, 10.1016/S0169-5002(00)80622-4 O'Reilly, 1996, Angiostatin induces and sustains dormancy of human primary tumors in mice, Nature. Med., 2, 689, 10.1038/nm0696-689 O'Reilly, 1997, Endostatin: an endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, 277, 10.1016/S0092-8674(00)81848-6 Folkman, 1998, Antiangiogenic gene therapy, Proc. Natl. Acad. Sci. USA, 95, 9064, 10.1073/pnas.95.16.9064 Hood, 2002, Tumor regression by targeted gene delivery to the neovasculature, Science, 296, 2404, 10.1126/science.1070200 Brooks, 1994, Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, Cell, 79, 1157, 10.1016/0092-8674(94)90007-8 Huser, 2001, MEK kinase activity is not necessary for Raf-1 function, EMBO J., 20, 1940, 10.1093/emboj/20.8.1940 Niethammer, 2002, A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth, Nat. Med., 8, 1369, 10.1038/nm1202-794